$-1.85 EPS Expected for Sage Therapeutics, Inc. (SAGE); Newmarket Has 1.1 Sentiment

April 24, 2018 - By Pete Kolinski

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Newmarket Corp (NEU) investors sentiment decreased to 1.1 in 2017 Q4. It’s down -0.12, from 1.22 in 2017Q3. The ratio worsened, as 103 hedge funds increased or started new positions, while 94 reduced and sold stakes in Newmarket Corp. The hedge funds in our database reported: 6.41 million shares, down from 6.85 million shares in 2017Q3. Also, the number of hedge funds holding Newmarket Corp in top ten positions decreased from 2 to 1 for a decrease of 1. Sold All: 25 Reduced: 69 Increased: 73 New Position: 30.

Analysts expect Sage Therapeutics, Inc. (NASDAQ:SAGE) to report $-1.85 EPS on May, 8.They anticipate $0.33 EPS change or 21.71% from last quarter’s $-1.52 EPS. After having $-1.75 EPS previously, Sage Therapeutics, Inc.’s analysts see 5.71% EPS growth. The stock decreased 0.89% or $1.3 during the last trading session, reaching $144.19. About 140,099 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 24, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Since December 14, 2017, it had 0 buys, and 4 sales for $37.32 million activity. Robichaud Albert had sold 60,000 shares worth $9.57M. PAUL STEVEN M also sold $10.00M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by Kanes Stephen. STARR KEVIN P also sold $9.96M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares.

Investors sentiment increased to 1.49 in 2017 Q4. Its up 0.28, from 1.21 in 2017Q3. It increased, as 27 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Fernwood Investment Ltd Limited Liability Company holds 0.75% or 8,466 shares. Da Davidson & holds 0.01% or 1,723 shares. Great Point Prns Limited Liability Company reported 5.62% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Rhenman And Prns Asset Management invested 2.34% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Axa stated it has 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Thrivent For Lutherans reported 0.01% stake. Bailard Inc holds 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 1,700 shares. State Board Of Administration Of Florida Retirement System accumulated 0.01% or 20,992 shares. Essex Mngmt Ltd Liability Company accumulated 6,431 shares or 0.14% of the stock. Amundi Pioneer Asset Inc owns 121,008 shares. Bancorporation Of Montreal Can accumulated 336 shares or 0% of the stock. Bank Of Ny Mellon has 0.07% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 1.62 million shares. Granite Point Cap Management Limited Partnership, Massachusetts-based fund reported 18,000 shares. Ra Management Ltd Company stated it has 6.27% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Northern Tru invested in 0.02% or 444,158 shares.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, September 3 by Leerink Swann. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Thursday, November 9. Stifel Nicolaus maintained the shares of SAGE in report on Thursday, December 7 with “Buy” rating. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Wednesday, January 31. BMO Capital Markets has “Buy” rating and $203.0 target. RBC Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, November 9 with “Buy” rating. The rating was maintained by SunTrust with “Buy” on Thursday, December 7. The stock has “Hold” rating by H.C. Wainwright on Friday, August 4. The rating was upgraded by Raymond James to “Strong Buy” on Wednesday, December 14. Canaccord Genuity maintained it with “Buy” rating and $11000 target in Friday, August 4 report. The firm earned “Buy” rating on Tuesday, September 12 by Needham.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $6.60 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

NewMarket Corporation, through its subsidiaries, engages in the petroleum additives businesses. The company has market cap of $4.71 billion. It offers lubricant additives for use in various vehicle and industrial applications, such as engine oils, transmission fluids, off-road powertrain and hydraulic systems, gear oils, hydraulic oils, turbine oils, metalworking fluids, and in other applications where metal-to-metal moving parts are utilized; and engine oil, driveline, and industrial additives. It has a 24.86 P/E ratio. The firm also provides fuel additives that are used to enhance the oil refining process and the performance of gasoline, diesel, biofuels, and other fuels to industry, government, original equipment manufacturers , and individual customers.

NewMarket Corporation (NYSE:NEU) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>